Walter Vifian

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 19 EPO patents. Top assignees: Hoffmann-La Roche Inc., Remynd Nv. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Walter Vifian. Retrieved from https://idiyas.com/inventor/walter-vifian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 35.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 19 (Patent Applications = 21)

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Olten, CH (2008)
Gelterkinden, CH (2012 - 2017)
Basel, CH (2019 - 2022)

Company Filing History:

14 out of 5,026

Hoffmann-La Roche Inc.

Years Active: 2008-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11440915 - Triazolo-azepine derivatives (2022-09-13),

2. 11414420 - Pyrimidine derivatives (2022-08-16),

3. 10696691 - BACE1 inhibitors (2020-06-30),

4. 10246468 - BACE1 inhibitors (2019-04-02),

5. 9808456 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease (2017-11-07),

6. 9751870 - Oxytocin receptor agonists for the treatment of CNS diseases (2017-09-05),

7. 9540397 - BACE1 inhibitors (2017-01-10),

8. 9346786 - Pyrrolidine compounds (2016-05-24),

9. 9226916 - Pyrrolidine derivatives (2016-01-05),

10. 9187440 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease (2015-11-17),

11. 9023852 - 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases (2015-05-05),

12. 8618303 - Pyrrolidine derivatives (2013-12-31),

13. 8507535 - Methyl-pyrrolidine ether derivatives (2013-08-13),

14. 8324250 - Piperidine derivatives as NK3 receptor antagonists (2012-12-04),

15. 8324248 - Piperidine derivatives as NK3 receptor antagonists (2012-12-04),

Title: Walter Vifian: Innovator in Pharmaceutical Compounds

Introduction

Walter Vifian is a notable inventor based in Gelterkinden, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various neurological conditions. With a total of 17 patents to his name, Vifian's work has the potential to impact many lives.

Latest Patents

Among his latest innovations are the Triazolo-azepine derivatives. This invention relates to compounds that can be utilized in the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica, and Down syndrome. Another significant contribution is his work on pyrimidine derivatives, which includes new compounds with various applications in pharmaceutical compositions and methods of use.

Career Highlights

Walter Vifian has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Remynd NV. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Vifian has collaborated with talented individuals such as Hasane Ratni and Matthias Heinrich Nettekoven. These partnerships have fostered innovation and have been instrumental in advancing his research.

Conclusion

Walter Vifian's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through scientific advancements. His work continues to pave the way for new treatments and therapies that can enhance the quality of life for many individuals.

Profile summary based on public USPTO records.